By filtration of normal human serum through a Sephadex G-2oo column, an anti-virus release factor (AVRF), which is capable of inhibiting the release of Epstein-Barr virus (EBV) from cells cultured in vitro,
It is conceivable that numerous non-immune mechanisms as well as immune mechanisms regulate the pathogenesis of and/or defence against virus infections in animals. Among the non-immune (or non-specific) mechanisms, a group of humoral factors categorized as 'virus inhibitors' present in normal body fluids, including serum and secretions (Allen et al. I958; Wassermann, I968) , probably provides natural host resistance. Most, if not all, of the inhibitors neutralize or inactivate virus infectivity, or prevent virus adsorption to cells, as their modes of action.
Recently we have reported (Sairenji & Hinuma, I975; Matsumoto et al. I98O) a new type of virus inhibitor in bovine serum as revealed by an in vitro test. This substance prevented the release of Epstein-Barr virus (EBV) from cells and thus reduced strikingly the production of extracellular virus. The anti-virus release factor (AVRF) has been partially purified by filtration through Sephadex G-2oo and the activity was found in fractions close to IgM. AVRF did not neutralize virus infectivity or inhibit intracellular virus growth.
Based on these findings, we predicted that such a factor may be present in human serum and block the spread of EBV in man, the natural host of EBV. Accordingly, we have looked for AVRF in normal human serum and have detected it after serum fractionation. Furthermore, another component, antagonistic to the activity of AVRF, is present concomitantly in the same serum. The latter has been termed anti-AVRF. The potency of these opposing factors is usually balanced in human serum and accounts for the neutral characteristic of the serum in the assay of EBV-release from cells. We report here the detection of these two factors in normal human serum and modulation of virus release from cells by these regulatory substances.
Twenty-seven ml of a normal seronegative adult serum (Nomura)was added to a Sephadex G-zoo column (2.7x I35 cm) and eluted with o.oI M-phosphate buffered saline, pH 7"z ( Fig. 0 . Fractions (IO ml) were monitored by spectrophotometer at 28o nm. Each fraction was assayed for both AVRF and anti-AVRF activities. AVRF activity was determined by its ability to inhibit extracellular production of EBV from the P3HR-I cell line: portions (oq ml) of the test sample (whole or fractionated serum) were added to o-9 ml of P3HRq cell suspension (3 x io~cells/ml) in RPMI-I64O medium supplemented with 5% foetal calf serum free from bovine AVRF (Sairenji & Hinuma, I975). After 7 days at 33 °C, the fluid portion was separated from the cells in the culture and titrated for infectivity as determined by early antigen (EA)-inducing units (EAIU; Sairenji & Hinuma, I973b). AVRF activity was expressed as an inhibitory index (I.I.) obtained as follows: the EAIU value of the culture containing AVRF was subtracted from that of the AVRF-free control culture and divided by the value of the control. A linear relationship between the I.I. and AVRF dose, as observed in bovine AVRF (Matsumoto et al. I98O) , made the assay of AVRF possible, and a value of o'5 of the I.I., obtained from the dose-response curve, was designated as one unit of AVRF activity. Anti-AVRF activity was determined in a test with P3HR-I cells. The sample (fraction of serum) was mixed with an equal volume of 5 units/ml of AVRF (F-I preparation in Fig. I ) and incubated for 3o min at 37 °C. Then o.I ml of the mixture was added to 0. 9 ml of the cell culture, followed by the same procedure used for the AVRF assay. Activity of anti-AVRF was expressed by an anti-inhibitory index (A.I.I.) calculated as follows: I.I. value of the test sample-containing culture was subtracted from that of the AVRF-containing control culture and divided by that of the control. A linear relationship between A.I.I. and anti-AVRF dose was observed and o'5 of A.I.I. was designated as one unit of anti-AVRF activity. Appropriate fractions were pooled as indicated by F-I, F-II and F-III (Fig. [ ). Fig. [ shows the profiles of both AVRF and anti-AVRF resulting from fractionation of a normal adult serum, lacking antibodies of EBV, by Sephadex G-zoo column chromatography. A single peak of AVRF activity was detected in the fractions (F-I) corresponding to those of IgM. On the other hand, most of the anti-AVRF activity was found in fractions (F-III) close to those of albumin but with a slightly more heterogeneous distribution than AVRF.
Three seronegative and four seropositive healthy adult sera were fractionated on a 
Sephadex G-zoo column (I'25 × 90 cm). Each of the pooled fractions, F-I, F-II and F-III
was concentrated to 2 ml by ultrafiltration and assayed for AVRF activity (units/mg protein), EBV neutralization (Sakamoto, I977) and anti-AVRF activity (units/rag protein).
As shown in Table I , AVRF, neutralization and anti-AVRF activities were found only in F-I, F-II and F-III, respectively, in all sera, except that there was no neutralization activity in F-II from the three seronegative individuals. F-II samples from the four seropositive individuals were not tested for both AVRF and anti-AVRF activities, because they contained neutralizing antibodies which interfere with assay of these activities. The F-I preparations (crude AVRF) usually had 20 to 42 units/mg protein of specific AVRF activity. This means that 2"4 to 5 #g protein/ml of the preparation corresponded to one unit AVRF which accounted for 50 % inhibition of the virus production in control (AVRF-free) cultures. By the use of 3 or 4 units/ml of F-I preparations, some biological characteristics of AVRF were established. These results are summarized as follows: (I) inhibition of EBV-release by AVRF was reversible, since lowered virus production (z × Io ~ EAIU/ml) by P3HR.-I cells cultured in a medium plus AVRF for 7 days increased to the level of control production (3 x io 5 EAIU/ml) after 7 days of continuous cultivation in the absence of AVRF. (z) AVRF did not neutralize EBV infectivity; the virus was mixed with an equal amount of the AVRF, incubated at 37 °C for I h and then titrated as described previously (Sairenji & Hinuma, I973b) . Titres of EBV infectivity in AVRF-free control virus and virus mixed with AVRF were 6.4 x Io 5 EAIU/ml and 7.2x IO 5 EAIU/ml respectively. (3) AVRF did not prevent adsorption of EBV to NC-37 (C-6) cells. This characteristic was determined by a procedure described previously (Sairenji & Hinuma, I973a). NC-37 (C-6) cells (z × io6/ml), which had been pre-incubated with the AVRF for 2 h at 37 °C, were absorbed with EBV (3"5 × Io5 EAIU/ml) in the presence of AVRF for I h at 37 °C. The control cells not treated with AVRF were incubated similarly ~¢ith EBV in the absence of AVRF. Titres of infectivity in the supernatants with and without AVRF were not significantly different, but were reduced to 2 x io 4 to z.8 × Io 4 EAIU/ml, indicating a marked adsorption of virus to cells. (4) AVRF-containing P3HR-I cells cultured for I week at 37 °C released only about one tenth the amount of EBV into the culture fluid, but no reduction of intracellular virus production was found in comparison with controls (AVRF-free cultures) and a rather higher titre was obtained; the culture with AVRF and the control culture showed 1.7 × Ion EAIU/Io7 cells and 0.6 x lo 6 EAIU/Io 7 ceils of intracellular virus, respectively. (5) Cap formation of EBV antigens on the surface of NC-37 (C-6) cells, without participation of antibody (Hinuma et al. I975) , was augmented by Short communications AVRF: in the presence of AVRF preparations, more than 3o% of cells formed caps but only 15% of cells capped in controls when incubated at 37 °C for 3o rain after virus adsorption.
The biological properties of anti-AVRF have not been determined yet. However, it is quite clear that AVRF mixed with a preparation of anti-AVRF (F-III) abolished activity completely. Normal seronegative human serum did not prevent virus release (Y. Hinuma et al. unpublished data) , probably due to the presence of excess anti-AVRF against AVRF in the sample. How AVRF and anti-AVRF change in amount and activity in various physiological and pathological conditions is of great interest.
In general, the virus multiplication cycle starts with virus attachment to cells and is completed with the release of virus particles from cells, after intracellular synthesis of virus progeny. The initial events and those occurring during replication within cells have been extensively investigated for many viruses, but relatively little attention has been focused on the final step of virus ' release' which is essential for multiple cycles of virus growth. The importance of inhibition of virus release for the prevention of virus disease, is exemplified by the neuraminidase of the influenza virion (Seto & Rott, I966) . Neuraminidase-inhibiting antibody, distinct from that against haemagglutinin, is infection-permissive but depresses virus replication and therefore disease (Schulman et al. 1968; Murphy et al. 1972; Couch et al. I974; Kilbourne et al. I975) . Perhaps the non-immune components, AVRF and anti-AVRF, as well as antibodies to a putative enzyme involved in the release of EBV, regulate or modulate the spreading of EBV in vivo by acting on the release step. Further information on the chemistry and biological significance of both AVRF and anti-AVRF will be sought after purification.
